Savara (NASDAQ:SVRA) Issues Earnings Results

Savara (NASDAQ:SVRA) posted its quarterly earnings results on Tuesday. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01), FiscalAI reports.

Savara Stock Performance

Savara stock traded down $0.21 during midday trading on Wednesday, hitting $4.12. The company’s stock had a trading volume of 1,951,801 shares, compared to its average volume of 1,317,712. Savara has a 1-year low of $1.89 and a 1-year high of $4.51. The company has a 50-day moving average price of $3.77 and a two-hundred day moving average price of $3.04. The company has a market cap of $712.09 million, a price-to-earnings ratio of -8.24 and a beta of 0.45. The company has a debt-to-equity ratio of 0.25, a current ratio of 11.08 and a quick ratio of 11.08.

Institutional Trading of Savara

Several large investors have recently bought and sold shares of SVRA. Rhumbline Advisers grew its position in Savara by 10.8% during the 2nd quarter. Rhumbline Advisers now owns 170,176 shares of the company’s stock worth $388,000 after acquiring an additional 16,634 shares during the last quarter. Prudential Financial Inc. acquired a new position in shares of Savara in the 2nd quarter valued at about $30,000. XTX Topco Ltd bought a new stake in shares of Savara in the 2nd quarter valued at $201,000. Invesco Ltd. boosted its position in shares of Savara by 35.4% during the 2nd quarter. Invesco Ltd. now owns 120,891 shares of the company’s stock worth $276,000 after purchasing an additional 31,633 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Savara by 14.2% during the second quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock valued at $118,000 after acquiring an additional 6,449 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on SVRA. HC Wainwright increased their target price on shares of Savara from $5.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, September 3rd. Guggenheim raised their price target on Savara from $8.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, September 9th. Lifesci Capital raised shares of Savara to a “strong-buy” rating in a research note on Tuesday, October 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Wednesday, October 8th. Finally, Oppenheimer lifted their price objective on Savara from $6.00 to $8.00 and gave the stock an “outperform” rating in a research note on Monday, September 8th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.83.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.